To prospectively study the effects of nimodipine administered early after stroke onset.
- Nimodipine (Nimotop®)Drug
Intervention Desc: Calcium channel blocker (L-type calcium channels)
Randomized. double-blind, placebo-controlled trial of 454 patients.
Patients were randomized to receive nimodipine 30 mg qid, po for 10 days or placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||All-cause mortality or dependency in daily life (Modified Rankin Scale score >3.11 ) 3 months after inclusion.|
|Secondary||Neurological status and blood pressure 24 hours after inclusion, mortality after 10 days, and adverse events.|